Cargando…
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that carries a cytotoxic drug (DM1) to HER2-positive cancer. The target of T-DM1 (HER2) is present also on cancer-derived exosomes. We hypothesized that exosome-bound T-DM1 may contribute to the activity of T-DM1. METHODS: Exoso...
Autores principales: | Barok, Mark, Puhka, Maija, Vereb, Gyorgy, Szollosi, Janos, Isola, Jorma, Joensuu, Heikki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930687/ https://www.ncbi.nlm.nih.gov/pubmed/29720111 http://dx.doi.org/10.1186/s12885-018-4418-2 |
Ejemplares similares
-
Trastuzumab emtansine: mechanisms of action and drug resistance
por: Barok, Mark, et al.
Publicado: (2014) -
Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy
por: Barok, Mark, et al.
Publicado: (2021) -
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
por: Barok, Mark, et al.
Publicado: (2011) -
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014) -
Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)